

Resource Summary Report

Generated by ASWG on Aug 14, 2026

Pacific Blue(TM) anti-human CD34

RRID:AB_1877197

Type: Antibody

Proper Citation

BioLegend Cat# 343512, RRID:AB_1877197

Antibody Information

URL: http://antibodyregistry.org/AB_1877197

Proper Citation: BioLegend Cat# 343512, RRID:AB_1877197

Target Antigen: CD34

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Pacific Blue(TM) anti-human CD34

Description: This monoclonal targets CD34

Target Organism: human

Clone ID: Clone 581

Antibody ID: AB_1877197

Vendor: BioLegend

Catalog Number: 343512

Alternative Catalog Numbers: 343511

Record Creation Time: 20250820T005127+0000

Record Last Update: 20250820T092247+0000

Ratings and Alerts

No rating or validation information has been found for Pacific Blue(TM) anti-human CD34.

No alerts have been found for Pacific Blue(TM) anti-human CD34.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Wang Y, et al. (2026) Efficient generation of human cDC1-like cells to detect and enhance tumor-reactive T cells via CD4+ T cell help. Cell reports methods, 101533.

Zeng J, et al. (2025) Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells. Cell stem cell, 32(2), 191.

Li Q, et al. (2025) Macro-scale, scaffold-assisted model of the human bone marrow endosteal niche using hiPSC-vascularized osteoblastic organoids. Cell stem cell, 32(12), 1941.

Ji RJ, et al. (2024) Epitope prime editing shields hematopoietic cells from CD123 immunotherapy for acute myeloid leukemia. Cell stem cell, 31(11), 1650.

Alhaj Hussien K, et al. (2023) Multimodal cartography of human lymphopoiesis reveals B and T/NK/ILC lineages are subjected to differential regulation. iScience, 26(10), 107890.

Keita S, et al. (2023) Distinct subsets of multi-lymphoid progenitors support ontogeny-related changes in human lymphopoiesis. Cell reports, 42(6), 112618.

Han W, et al. (2023) Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs. Cell stem cell, 30(12), 1624.

Biancon G, et al. (2022) Precision analysis of mutant U2AF1 activity reveals deployment of stress granules in myeloid malignancies. Molecular cell, 82(6), 1107.

Van Egeren D, et al. (2021) Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell stem cell, 28(3), 514.

Ueda K, et al. (2021) MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer cell, 39(4), 529.

Qiu J, et al. (2020) Retinoic Acid Promotes Endothelial Cell Cycle Early G1 State to Enable Human Hemogenic Endothelial Cell Specification. Cell reports, 33(9), 108465.

Xu H, et al. (2019) Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility. *Cell stem cell*, 24(4), 566.

Osorio FG, et al. (2018) Somatic Mutations Reveal Lineage Relationships and Age-Related Mutagenesis in Human Hematopoiesis. *Cell reports*, 25(9), 2308.